---
title: "Bezuclastinib in Nonadvanced systemic mastocytosis: Product information and disease description"
description: "Formulary evidence on Bezuclastinib in Nonadvanced systemic mastocytosis: Product information and disease description. Covers Product description and Place of product in therapy. 64 evidence topics quoted from 45 sources."
canonical: "https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/product-information-and-disease-description"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Bezuclastinib in Nonadvanced systemic mastocytosis: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Orphan designation and approval status

> “Date Designated: 03/17/2023”
> “Orphan Designation: Treatment of Mastocytosis”
> “FDA Orphan Approval Status: Not FDA Approved for Orphan Indication”

Source: [FDA orphan drug designation record for bezuclastinib (2023)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=929722)

<a id="topic-2.1.1-2"></a>

##### Regulatory status: Under review; NDA submitted December 2025 and accepted March 2026

> “November 5, 2026”
> “Potential FDA approval of bezuclastinib in NonAdvSM – PDUFA date of December 30, 2026”

Source: [Cogent Biosciences third quarter 2026 financial results (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-reports-recent-business-highlights-and-12)

> “March 16, 2026”
> “today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for bezuclastinib in patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) and assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2026.”

Source: [Cogent Biosciences NonAdvSM new drug application acceptance announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-fda-acceptance-new-drug-application)

> “December 30, 2025”
> “submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM).”

Source: [Cogent Biosciences NonAdvSM new drug application submission announcement (2025)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-submission-new-drug-application)

<a id="topic-2.1.1-3"></a>

##### FDA review timeline and advisory committee

> “Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2026.”
> “there is no plan to hold an advisory committee”

Source: [Cogent Biosciences NonAdvSM new drug application acceptance announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-fda-acceptance-new-drug-application)

<a id="topic-2.1.1-4"></a>

##### Breakthrough Therapy Designation: designated populations

> “NonAdvanced Systemic Mastocytosis (NonAdvSM) patients previously treated with avapritinib as well as in patients with Smoldering Systemic Mastocytosis”

Source: [Cogent Biosciences Breakthrough Therapy designation announcement (2025)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-fda-breakthrough-therapy)

<a id="topic-2.1.1-5"></a>

##### Launch: Anticipated in the second half of 2026

> “pending regulatory approval, the company expects to launch bezuclastinib commercially in the United States in the second half of 2026.”

Source: [Cogent Biosciences investor overview](https://investors.cogentbio.com/)

> “Pending FDA approval(s), launch bezuclastinib in the second half of 2026”

Source: [Cogent Biosciences first quarter 2026 financial results (2026)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526205124/cogt-ex99_1.htm)

> “The Company’s NDA for NonAdvanced Systemic Mastocytosis is under FDA review, with a PDUFA target action date of December 30, 2026”
> “ready for the potential launches later this year”

Source: [Cogent Biosciences AdvSM new drug application acceptance announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-fda-acceptance-new-drug-1)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Product and manufacturer

> “Generic Name: bezuclastinib”
> “Sponsor: Cogent Biosciences, Inc.”

Source: [FDA orphan drug designation record for bezuclastinib (2023)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=929722)

<a id="topic-2.1.2.1-2"></a>

###### Manufacturer: Cogent Biosciences

> “Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM).”

Source: [Cogent Biosciences NonAdvSM new drug application submission announcement (2025)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-submission-new-drug-application)

<a id="topic-2.1.2.1-3"></a>

###### Brand name

No evidence found.

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Investigational tablet formulations

> “Bezuclastinib Tablets (Formulation A)”
> “Bezuclastinib Tablets (Formulation B)”

Source: [MD Anderson Cancer Center](https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2021-0880.html)

<a id="topic-2.1.2.2-2"></a>

###### Marketed dosage strengths

Not applicable.

<a id="topic-2.1.2.2-3"></a>

###### Cogent clinical drug-product safety data sheet

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### Mechanism-based drug classification

> “type 1 tyrosine kinase inhibitor (TKI)”

Source: [Blood (2023)](https://scholars.duke.edu/publication/1664410)

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Population under investigation

> “patients with nonadvanced systemic mastocytosis (NonAdvSM)”

Source: [MD Anderson Cancer Center](https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2021-0880.html)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Drug class and mechanism of action

> “an oral, potent, and selective type 1 tyrosine kinase inhibitor (TKI) with activity against KIT D816V.”

Source: [Blood (2023)](https://scholars.duke.edu/publication/1664410)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Nonclinical central nervous system exposure

> “Minimal brain exposure with no evidence of CNS-related effects in nonclinical safety pharmacology and toxicology studies”

Source: [ASH (2022)](https://www.cogentbio.com/wp-content/uploads/2022/12/ASH-2022-Summit-TiP.pdf)

Additional sources: [Guarnieri et al. (2021)](https://ashpublications.org/blood/article/138/Supplement%201/4595/478022/Preclinical-Data-with-KIT-D816V-Inhibitor)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Pharmacokinetics: healthy-adult, single-dose formulation study

> “Bezuclastinib was slowly absorbed after oral administration, reaching median time to maximum concentration 12 to 16 hours post dose.”

Source: [Patent WO2024138005A1 (2024)](https://patents.google.com/patent/WO2024138005A1/en)

<a id="topic-2.1.2.6.3-2"></a>

###### Elimination half-life: healthy-adult, single-dose formulation study

> “48.6 to 71.4 hours.”

Source: [Patent WO2024138005A1 (2024)](https://patents.google.com/patent/WO2024138005A1/en)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

No evidence found.

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Bezuclastinib

<a id="topic-2.1.2.9.1-1"></a>

###### SUMMIT protocol exclusion: recent strong CYP3A4 inhibition or induction

> “Received strong CYP3A4 inhibitors or inducers within 14 days or 5 drug half-lives before the first dose of study drug”

Source: [Dana-Farber Cancer Institute](https://www.dana-farber.org/clinical-trials/22-592)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Bezuclastinib on Other Drugs

No evidence found.

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Bezuclastinib dose in SUMMIT Part 2

> “100mg every day”

Source: [Rein et al. (2026a)](https://ncoda.org/nohma/2026isf-a25p25/)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### SUMMIT protocol: oral administration and treatment cycles

> “administered orally, once daily, for 28 days of each 4-week cycle”

Source: [ASH (2022)](https://www.cogentbio.com/wp-content/uploads/2022/12/ASH-2022-Summit-TiP.pdf)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Expanded access

> “Cogent has initiated Bezuclastinib Expanded Access Protocols (EAP) for patients with GIST or SM who meet disease-specific protocol inclusion and exclusion criteria.”
> “EAP@cogentbio.com”

Source: [Cogent Biosciences](https://www.cogentbio.com/bezuclastinib/)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### SUMMIT background therapy

> “best supportive care (BSC)”

Source: [MD Anderson Cancer Center](https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2021-0880.html)

<a id="topic-2.1.2.12-2"></a>

###### SUMMIT protocol: maximum concomitant prednisone dose

> “≤10 mg/day of prednisone”

Source: [Dana-Farber Cancer Institute](https://www.dana-farber.org/clinical-trials/22-592)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Bezuclastinib on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### Bezuclastinib-specific quality-measure findings

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Comparator assessment of avapritinib by IQWiG: assessed population

> “Adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment”

Source: [IQWiG](https://www.iqwig.de/en/projects/a25-136.html)

<a id="topic-2.1.2.14-2"></a>

###### Comparator assessment of avapritinib by IQWiG: assessment result

> “Added benefit not proven”

Source: [IQWiG](https://www.iqwig.de/en/projects/a25-136.html)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Nonadvanced systemic mastocytosis subtypes

> “non-advanced i.e., indolent SM (ISM), bone marrow mastocytosis, and smoldering SM”

Source: [Jørgensen et al. (2025)](https://link.springer.com/article/10.1007/s10654-024-01195-5)

Additional sources: [Farmer and Radia (2024)](https://pubmed.ncbi.nlm.nih.gov/39187708/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Nonadvanced systemic mastocytosis

<a id="topic-2.2.1.2.1-1"></a>

###### Denmark: mean annual ISM incidence, 1997–2021

| Population and unit | Incidence and 95% confidence interval |
| --- | --- |
| ISM, per 100,000 person-years | “0.43 (0.32–0.55)” |

Source: [Jørgensen et al. (2025)](https://link.springer.com/article/10.1007/s10654-024-01195-5)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Nonadvanced systemic mastocytosis

<a id="topic-2.2.1.2.2-1"></a>

###### Epidemiology in Denmark: study classification

> “all patients with non-advanced SM were characterized as ISM.”

Source: [Jørgensen et al. (2025)](https://link.springer.com/article/10.1007/s10654-024-01195-5)

<a id="topic-2.2.1.2.2-2"></a>

###### Epidemiology in Denmark: ISM prevalence as of January 1, 2022

> “The prevalences of MIS and ISM were 13.94 per 100,000 persons (95% CI: 12.89–15.04) and 9.36 per 100,000 (95% CI: 8.51–10.28), respectively”

Source: [Jørgensen et al. (2025)](https://link.springer.com/article/10.1007/s10654-024-01195-5)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Denmark: 10-year survival probability in the ISM group

> “The 10-year survival probability was 86.8% (95%CI: 79.9–94.4%), 90.1% (95%CI: 87.8–92.5%), and 87.1% (95%CI: 83.6–90.8%) for CM, MIS, and ISM, respectively.”

Source: [Jørgensen et al. (2025)](https://link.springer.com/article/10.1007/s10654-024-01195-5)

Additional sources: [Pongdee et al. (2026)](https://www.sciencedirect.com/science/article/pii/S2772829326000639)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Pathophysiology

> “KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells.”

Source: [Cogent Biosciences 2026 AAAAI SUMMIT posters announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-multiple-summit-posters-2026-aaaai)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Diagnostic evaluation and screening

> “Timely diagnosis of systemic mastocytosis (SM) remains challenging because of care heterogeneity.”

Source: [McMurray et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11418066/)

<a id="topic-2.2.1.5-2"></a>

###### Updated diagnostic criteria and classification of mast cell disorders

> “CD30 expression in MC now qualifies as a minor SM criterion”

Source: [Valent et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8659997/)

<a id="topic-2.2.1.5-3"></a>

###### Consensus diagnostic rule: major and minor criteria

> “at least 1 major and 1 minor or 3 minor SM criteria are fulfilled”

Source: [Valent et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8659997/)

Additional sources: [Costa et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37256917/); [Tse et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11372574/); [Zeiger et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39477015/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Dermatological symptoms: MS2D2 domains

> “Itching; Flushing; Skin redness; Covered with spots.”

Source: [Marcus et al. (2026)](https://link.springer.com/article/10.1007/s11136-026-04291-z)

<a id="topic-2.2.1.6-2"></a>

###### Gastrointestinal and pain symptoms: MS2D2 domains

> “Nausea; Abdominal pain; Bone pain; Headache.”

Source: [Marcus et al. (2026)](https://link.springer.com/article/10.1007/s11136-026-04291-z)

<a id="topic-2.2.1.6-3"></a>

###### Neurocognitive symptoms: MS2D2 domains

> “Difficulty concentrating; Difficulty remembering things.”

Source: [Marcus et al. (2026)](https://link.springer.com/article/10.1007/s11136-026-04291-z)

<a id="topic-2.2.1.6-4"></a>

###### Fatigue symptoms: MS2D2 domains

> “Feeling of tiredness.”

Source: [Marcus et al. (2026)](https://link.springer.com/article/10.1007/s11136-026-04291-z)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Skeletal morbidity and fracture potential

> “osteosclerosis, osteopenia, osteoporosis, or osteolysis with the potential for pathologic fractures.”

Source: [Valent et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8659997/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Nonadvanced systemic mastocytosis

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Humanistic and productivity burden: U.S. systemic mastocytosis survey

> “Over one half of patients (54%) reduced their work hours because of SM, and 64% avoided leaving home because of symptoms.”

Source: [Mesa et al. (2022a)](https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.34420)

Additional sources: [Zeiger et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39477015/); [Mesa et al. (2022b)](https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.34421)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### U.S. healthcare costs: nonadvanced SM versus matched non-SM controls

> “Mean±SD (median) post-index total medical costs were $24,588±51,385 ($9,019) vs. $14,419±33,449 ($4,035) (P<0.001).”

Source: [Norregaard et al. (2021)](https://www.blueprintmedinfo.com/uploads/AMCP-2021.-Non-advanced-SM-poster_.pdf)

<a id="topic-2.2.1.8.2-2"></a>

###### Healthcare resource utilization and medication burden

> “Patients with ISM take more classes of medications compared to control patients (14.68 vs 5.79)”

Source: [Pongdee et al. (2025)](https://www.blueprintmedicines.com/wp-content/uploads/2025/03/Blueprint-Medicines-AAAAI-WAO-2025-ISM-Mayo-Clinic-Electronic-Health-Records-Real-World-Natural-History-Oral-1.pdf)

<a id="topic-2.2.1.8.2-3"></a>

###### SUMMIT: changes in best supportive care medication use

> “50% of patients reported a dose reduction and/or discontinuation of best supportive care medicines during the treatment period at week 48”

Source: [Cogent Biosciences 2026 AAAAI additional SUMMIT data announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-highlights-additional-data-six-bezuclastinib)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Nonadvanced systemic mastocytosis on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Patient and caregiver employment burden

> “patients and caregivers must take an unexpected leave of absence from work”

Source: [Canada’s Drug Agency avapritinib reimbursement recommendation (2026)](https://www.ncbi.nlm.nih.gov/books/NBK624169/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

No evidence found.

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Trigger Avoidance and Patient Education

<a id="topic-2.2.2.1.1-1"></a>

###### Avoidance of individual mast-cell activation triggers

> “Avoidance of triggering factors”

Source: [Bulai Livideanu et al. (2025)](https://ojrd.biomedcentral.com/articles/10.1186/s13023-025-03764-7)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 H1 and H2 Antihistamines

<a id="topic-2.2.2.1.2-1"></a>

###### Histamine-receptor blockade

> “anti-H1, anti-H2”

Source: [Bulai Livideanu et al. (2025)](https://ojrd.biomedcentral.com/articles/10.1186/s13023-025-03764-7)

<a id="topic-2.2.2.1.2-2"></a>

###### Second-generation H1 antihistamines

> “Second-generation H1 antihistamines form the cornerstone of symptomatic therapy.”

Source: [Siebenhaar et al. (2025a)](https://link.springer.com/article/10.1007/s40629-025-00327-x)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Proton Pump Inhibitors

<a id="topic-2.2.2.1.3-1"></a>

###### Additional acid suppression

> “proton pump inhibitor (off-label)”

Source: [Bulai Livideanu et al. (2025)](https://ojrd.biomedcentral.com/articles/10.1186/s13023-025-03764-7)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Leukotriene Receptor Antagonists

<a id="topic-2.2.2.1.4-1"></a>

###### Leukotriene-pathway inhibition

> “Leukotriene inhibitors (montelukast) (off-label)”

Source: [Bulai Livideanu et al. (2025)](https://ojrd.biomedcentral.com/articles/10.1186/s13023-025-03764-7)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Mast Cell Stabilizers

<a id="topic-2.2.2.1.5-1"></a>

###### Mast-cell stabilization

> “disodium cromoglycate”

Source: [Bulai Livideanu et al. (2025)](https://ojrd.biomedcentral.com/articles/10.1186/s13023-025-03764-7)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Epinephrine

<a id="topic-2.2.2.1.6-1"></a>

###### Emergency preparedness: prior severe anaphylaxis or insect venom allergy

> “two adrenaline autoinjectors are recommended.”

Source: [Siebenhaar et al. (2025a)](https://link.springer.com/article/10.1007/s40629-025-00327-x)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Corticosteroids

<a id="topic-2.2.2.1.7-1"></a>

###### Severe refractory symptoms: short-term glucocorticoids

> “low-dose glucocorticoids”
> “may be used short-term.”

Source: [Siebenhaar et al. (2025a)](https://link.springer.com/article/10.1007/s40629-025-00327-x)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 Anti-IgE Monoclonal Antibodies

<a id="topic-2.2.2.1.8-1"></a>

###### Recurrent uncontrolled anaphylaxis: anti-IgE therapy

> “omalizumab (used off-label)”

Source: [Siebenhaar et al. (2025a)](https://link.springer.com/article/10.1007/s40629-025-00327-x)

<a id="heading-2.2.2.1.9"></a>

###### 2.2.2.1.9 KIT Tyrosine Kinase Inhibitors

<a id="topic-2.2.2.1.9-1"></a>

###### Existing FDA-approved targeted treatment: avapritinib

> “Trade Name: Ayvakit”
> “Marketing Approval Date: 05/22/2023”
> “Approved Labeled Indication: treatment of adult patients with indolent systemic mastocytosis (ISM)”

Source: [FDA orphan drug designation record for avapritinib (2023)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=506515)

<a id="topic-2.2.2.1.9-2"></a>

###### Avapritinib dose for ISM

> “The recommended dosage of AYVAKIT is 25 mg orally once daily in patients with ISM.”

Source: [AYVAKIT prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf)

Additional sources: [Chifotides and Bose (2025)](https://pubmed.ncbi.nlm.nih.gov/39168723/); [Costanzo et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40471046/); [Akin (2023)](https://pubmed.ncbi.nlm.nih.gov/37758410/)

<a id="heading-2.2.2.1.10"></a>

###### 2.2.2.1.10 Cytoreductive Therapies

<a id="topic-2.2.2.1.10-1"></a>

###### Selected refractory mediator symptoms or bone disease

> “severe, refractory mediator symptoms or bone disease”
> “cladribine”
> “peginterferon alfa-2a”

Source: [NCCN (2024)](https://doi.org/10.6004/jnccn.2024.0030)

<a id="heading-2.2.2.1.11"></a>

###### 2.2.2.1.11 Bone-directed Therapies

<a id="topic-2.2.2.1.11-1"></a>

###### Bisphosphonates for skeletal disease

> “Anti-osteoporotic treatment with bisphosphonates”

Source: [Bulai Livideanu et al. (2025)](https://ojrd.biomedcentral.com/articles/10.1186/s13023-025-03764-7)

<a id="heading-2.2.2.1.12"></a>

###### 2.2.2.1.12 Venom Immunotherapy

<a id="topic-2.2.2.1.12-1"></a>

###### Severe anaphylaxis following Hymenoptera stings

> “Lifelong desensitization”

Source: [Bulai Livideanu et al. (2025)](https://ojrd.biomedcentral.com/articles/10.1186/s13023-025-03764-7)

<a id="heading-2.2.2.1.13"></a>

###### 2.2.2.1.13 Vascular Laser Therapy

<a id="topic-2.2.2.1.13-1"></a>

###### Telangiectatic or pigmentary skin lesions

> “Vascular laser treatment”

Source: [Bulai Livideanu et al. (2025)](https://ojrd.biomedcentral.com/articles/10.1186/s13023-025-03764-7)

<a id="heading-2.2.2.1.14"></a>

###### 2.2.2.1.14 Clinical Trials

<a id="topic-2.2.2.1.14-1"></a>

###### Symptomatic ISM and SSM

> “Enrollment in a clinical trial is a preferred option for these patients.”

Source: [NCCN (2024)](https://doi.org/10.6004/jnccn.2024.0030)

<a id="topic-2.2.2.1.14-2"></a>

###### French guidelines for nonadvanced mastocytosis in adults

> “In addition, bezuclastinib, another TKI specific to D816V, is being evaluated in a study (SUMMIT) involving several European centers”

Source: [Bulai Livideanu et al. (2025)](https://ojrd.biomedcentral.com/articles/10.1186/s13023-025-03764-7)

<a id="heading-2.2.2.1.15"></a>

###### 2.2.2.1.15 Limitations of Current Therapies

<a id="topic-2.2.2.1.15-1"></a>

###### Summary

Current care includes trigger avoidance, symptom-directed medicines, anaphylaxis preparedness, and treatment of skeletal complications. Avapritinib is FDA approved for adults with ISM. SUMMIT nevertheless enrolled participants with inadequate symptom control despite at least two anti-mediator therapies. The available evidence therefore describes a population with persistent symptoms on existing care; it does not establish that all treated people with nonadvanced SM require a KIT inhibitor. The effect of KIT inhibition on disease progression is not established.

Source: [Bulai Livideanu et al. (2025)](https://ojrd.biomedcentral.com/articles/10.1186/s13023-025-03764-7); [Siebenhaar et al. (2025a)](https://link.springer.com/article/10.1007/s40629-025-00327-x); [FDA orphan drug designation record for avapritinib (2023)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=506515); [Rein et al. (2026b)](https://ncoda.org/efficacy_and_safety_results_pos/); [Syal et al. (2025)](https://link.springer.com/article/10.1007/s00277-025-06475-y)

<a id="topic-2.2.2.1.15-2"></a>

###### Review focused on indolent systemic mastocytosis

> “The true impact of KIT inhibition on disease progression is also not known.”

Source: [Syal et al. (2025)](https://link.springer.com/article/10.1007/s00277-025-06475-y)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

The documented use of bezuclastinib is investigational. SUMMIT Part 2 evaluated 100 mg daily with best supportive care in nonadvanced SM with inadequate symptom control despite at least two anti-mediator therapies. Expanded-access protocols are described for eligible people with SM, subject to protocol-specific criteria. These trial and expanded-access arrangements do not constitute an approved routine-care indication.

Source: [FDA orphan drug designation record for bezuclastinib (2023)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=929722); [Rein et al. (2026a)](https://ncoda.org/nohma/2026isf-a25p25/); [Rein et al. (2026b)](https://ncoda.org/efficacy_and_safety_results_pos/); [Cogent Biosciences](https://www.cogentbio.com/bezuclastinib/)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### SUMMIT: bezuclastinib-treated subgroups, week 24 within-arm mean MS2D2 TSS change

| Subgroup | Mean change |
| --- | --- |
| Smoldering SM | “-35.6” |
| Prior avapritinib exposure | “-21.6” |

Source: [Rein et al. (2026b)](https://ncoda.org/efficacy_and_safety_results_pos/)

<a id="topic-2.2.2.3-2"></a>

###### Treatment-by-subgroup interaction testing

No evidence found.

Additional sources: [Fahrenholz et al. (2026)](https://doi.org/10.1016/j.jaci.2025.12.527)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Standardized screening and diagnostic testing

> “Standardization of screening and diagnostic testing improves SM diagnosis and KIT p.D816V detection rates.”

Source: [McMurray et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11418066/)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Association of symptom improvement with an objective disease marker

> “Symptom improvement significantly correlated with serum tryptase reduction”
> “p < 0.001, r = 0.39”

Source: [George et al. (2026)](https://www.cogentbio.com/wp-content/uploads/AAAAI-2026-Summit-Correlational.pdf)

## Related pages
- [Bezuclastinib: Nonadvanced systemic mastocytosis](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: Terms and abbreviations](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/terms-and-abbreviations.md)
- [Bezuclastinib: Nonadvanced systemic mastocytosis](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/executive-summary.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: Clinical evidence](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/clinical-evidence.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: Economic information and modeling report](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/economics) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/economics.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: References](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/references) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/references.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: prevalence by geography](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/prevalence) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/prevalence.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/cost-effectiveness-analyses.md)
